Talis Biomedical to Announce Fourth Quarter and Full Year Financial Results on March 15, 2022

Rhea-AI Summary

Talis Biomedical Corporation (TLIS) announced its plans to report fourth quarter and full year 2021 financial results on March 15, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) for interested stakeholders. The company is focused on advancing health equity through accurate infectious disease testing, deploying its Talis One system for rapid molecular testing. The Talis One COVID-19 Test System has received Emergency Use Authorization from the FDA for multiple healthcare settings.

Positive

• FDA granted Emergency Use Authorization for Talis One COVID-19 Test System.

Negative

• None.

MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report fourth quarter and full year 2021 financial and operational results on Tuesday, March 15, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Interested parties may access the live call via telephone by dialing 833-715-1329 for participants in the U.S. or Canada and 430-775-1933 for international callers, using conference ID 3692993. A live and archived webcast of the event can be accessed via the News & Events page of the investor section of Talis Biomedical’s website at www.talis.bio.

About Talis Biomedical
Talis is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One^TM system to enable accurate, low cost, and rapid molecular testing. The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for use of the Talis One COVID-19 Test System in a variety of healthcare settings. For more information, visit talisbio.com.

Contact
Media & Investors
Emily Faucette
ir@talisbio.com
415-595-9407

 

FAQ

When will Talis Biomedical report Q4 and full year 2021 results?

Talis Biomedical will report its Q4 and full year 2021 results on March 15, 2022, after market close.

What time is the Talis Biomedical conference call on March 15, 2022?

The Talis Biomedical conference call is scheduled for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on March 15, 2022.

What is the purpose of Talis Biomedical's Talis One system?

The Talis One system is designed for accurate, low-cost, and rapid molecular testing of infectious diseases.

Has Talis Biomedical received FDA approval for its testing system?

Yes, the Talis One COVID-19 Test System has received Emergency Use Authorization from the FDA.